Drugs / dexfadrostat phosphate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03046589 | Mar 2017 → Mar 2018 | — | Damian Pharma AG | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04007406 | Nov 2019 → May 2022 | primary aldosteronism | Damian Pharma AG | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dexfadrostat phosphate | “We evaluated the safety and efficacy of dexfadrostat phosphate (DP13), a novel aldosterone synthase (CYP11B2) inhibitor, in healthy participants.” PMID 36914591 ↗ Apr 2023 |
| Known as | DP13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03046589 ↗ |
| Action | Inhibit | “a novel aldosterone synthase (CYP11B2) inhibitor” PMID 36914591 ↗ Apr 2023 |
| Route | Oral | “received oral DP13 4, 8 or 16 mg once daily for 8 days” PMID 36914591 ↗ Apr 2023 |
| Target | CYP11B2 | “a novel aldosterone synthase (CYP11B2) inhibitor” PMID 36914591 ↗ Apr 2023 |